Rapid Titration With Intravenous Oxycodone for Severe Cancer Pain and Oral Conversion Ratio

被引:7
|
作者
Mercadante, Sebastiano [1 ]
Adile, Claudio
Ferrera, Patrizia
Lo Cascio, Alessio
Casuccio, Alessandra
机构
[1] La Maddalena Canc Ctr, Main Reg Ctr Pain Relief & Support Palliat Care, Via San Lorenzo 312, I-90146 Palermo, Italy
关键词
Cancer pain; Intravenous oxycodone; Opioids; Dose titration; Palliative care; MORPHINE; INTENSITY;
D O I
10.1016/j.jpainsymman.2022.09.004
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Context. to assess a dose titration with intravenous oxycodone to achieve rapid pain relief of cancer pain of severe intensity. The second objective was to provide a conversion ratio with the oral route.Methods. Cancer patients admitted for severe pain were prospectively assessed. At admission (T0) previous opioid doses were recorded. Edmonton symptom assessment scale (ESAS) was collected from T0 until the conclusion of the observation. Intravenous boluses of oxycodone were given until the initial signs of significant analgesia were detected. The effective dose was multiplied for six and given as intravenous continuous infusion. When the patient was considered stabilized the intravenous daily dose was converted to oral oxycodone using an initial ratio of 1:2. Subsequently, doses of oral oxycodone were changed according to the clinical situation.Results. Twenty-nine patients were examined. A mean effective bolus dose of oxycodone was 9.5 mg (SD 8.0) allowed to achieve a meaningful pain relief in a mean of 10.4 minutes (SD 3.3). The mean initial and the final infusion doses were 51.0 mg/day (standard deviation 40.9) and 69.7 mg/day ( standard deviation76.6), respectively. A significant change in pain intensity was observed at the different time intervals (P<0.0005). Conversion to oral route occurred after a mean of 2.7 days (standard deviation1.2) of intravenous oxycodone. The final mean conversion ratio was 1:2,12 ( standard deviation0.36).Conclusion. Rapid intravenous oxycodone dose titration resulted in rapid pain relief. The intravenous-oral conversion ratio of 1:2 is reliable. Further studies are necessary to confirm this preliminary observation. J Pain Symptom Manage 2022;64:532-536.(c) 2022 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:532 / 536
页数:5
相关论文
共 50 条
  • [21] A Strategy for Conversion From Subcutaneous to Oral Ketamine in Cancer Pain Patients: Effect of a 1:1 Ratio
    Angel Benitez-Rosario, Miguel
    Salinas-Martin, Antonio
    Gonzalez-Guillermo, Toribio
    Feria, Manuel
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2011, 41 (06) : 1098 - 1105
  • [22] Analgesic effectiveness and tolerability of oral oxycodone/naloxone and pregabalin in patients with lung cancer and neuropathic pain: an observational analysis
    De Santis, Stefano
    Borghesi, Cristina
    Ricciardi, Serena
    Giovannoni, Daniele
    Fulvi, Alberto
    Migliorino, Maria Rita
    Marcassa, Claudio
    ONCOTARGETS AND THERAPY, 2016, 9 : 4043 - 4052
  • [23] Oral Oxycodone Compared With Intravenous Morphine Sulfate for Pain Management of Isolated Limb Trauma; a Randomized Clinical Trial
    Eizadi, Parisa
    Jalili, Mohammad
    Dehpour, Ahmadreza
    EMERGENCY, 2018, 6 (01):
  • [24] Efficacy and Safety of Oxycodone Injection for Relieving Cancer Pain: A Study in Japan Consisting of Two Open Trials for Intravenous and Subcutaneous Administration
    Yoshimoto, Tetsusuke
    Ryu, Emi
    Tomiyasu, Shiro
    Hojo, Minoru
    Kokubu, Hideya
    Matoba, Motohiro
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2018, 41 (06) : 850 - 857
  • [25] Oral Morphine Prescribing Practices in Severe Cancer Pain
    Barathi, B.
    INDIAN JOURNAL OF PALLIATIVE CARE, 2009, 15 (02) : 127 - 131
  • [26] Clinical Study on Fluvoxamine Combined with Oxycodone Prolonged-Release Tablets in Treating Patients with Moderate to Severe Cancer Pain
    Xiao, Yang
    Liu, Jun
    Huang, Xin-En
    Ca, Li-Hua
    Ma, Yi-Min
    Wei, Wei
    Zhang, Rong-Xia
    Huang, Xiao-Hong
    Chang, Juan
    Wu, Yi-Jia
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (23) : 10445 - 10449
  • [27] Efficacy and Tolerability of Oxycodone Hydrochloride Controlled-Release Tablets in Moderate to Severe Cancer Pain
    Hongming Pan
    Zaiyun Zhang
    Yiping Zhang
    Nong Xu
    Liqin Lu
    Chunfeng Dou
    Yong Guo
    Shixiu Wu
    Jianhua Yue
    Dongping Wu
    Yuechu Dai
    Clinical Drug Investigation, 2007, 27 : 259 - 267
  • [28] Extreme Doses of Intravenous Methadone for Severe Pain in Two Children With Cancer
    Rasmussen, Vinni Faber
    Lundberg, Vicki
    Jespersen, Torben Worsoe
    Hasle, Henrik
    PEDIATRIC BLOOD & CANCER, 2015, 62 (06) : 1087 - 1090
  • [29] Initial Intrathecal Dose Titration and Predictors of Early Dose Escalation in Patients With Cancer Using a 100:1 Oral to Intrathecal Morphine Conversion Ratio
    Sindt, Jill E.
    Odell, Daniel W.
    Tariq, Rayhan
    Presson, Angela P.
    Zhang, Chong
    Brogan, Shane E.
    NEUROMODULATION, 2021, 24 (07): : 1157 - 1166
  • [30] Six- versus 12-h conversion method from intravenous to transdermal fentanyl in chronic cancer pain: a randomized study
    Nomura, Motoo
    Kamata, Minoru
    Kojima, Hiroyuki
    Hayashi, Kenji
    Kozai, Masasuke
    Sawada, Satoshi
    SUPPORTIVE CARE IN CANCER, 2011, 19 (05) : 691 - 695